labetalol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| aromatic ring -CH(-OH)-CH2-NH-R | 1531 | 36894-69-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | O |
| 0.60 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 16 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 2.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 104.53 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 4.80 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 23 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.50 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.40 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 1, 1984 | FDA | CNTY LINE PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 205.61 | 14.01 | 165 | 7936 | 155382 | 63325539 |
| Pre-eclampsia | 173.92 | 14.01 | 59 | 8042 | 9074 | 63471847 |
| Caesarean section | 154.90 | 14.01 | 64 | 8037 | 16968 | 63463953 |
| Premature baby | 136.42 | 14.01 | 62 | 8039 | 20673 | 63460248 |
| Premature delivery | 125.41 | 14.01 | 66 | 8035 | 30215 | 63450706 |
| Maternal exposure during pregnancy | 93.35 | 14.01 | 127 | 7974 | 219935 | 63260986 |
| Foetal growth restriction | 77.62 | 14.01 | 31 | 8070 | 7522 | 63473399 |
| Premature labour | 59.67 | 14.01 | 30 | 8071 | 12474 | 63468447 |
| Patent ductus arteriosus | 49.14 | 14.01 | 19 | 8082 | 4231 | 63476690 |
| Low birth weight baby | 45.86 | 14.01 | 21 | 8080 | 7108 | 63473813 |
| Foetal exposure during pregnancy | 44.38 | 14.01 | 35 | 8066 | 31927 | 63448994 |
| Pregnancy | 42.05 | 14.01 | 36 | 8065 | 36800 | 63444121 |
| Haemangioma congenital | 41.62 | 14.01 | 10 | 8091 | 442 | 63480479 |
| HELLP syndrome | 37.69 | 14.01 | 11 | 8090 | 1033 | 63479888 |
| Foetal death | 34.59 | 14.01 | 20 | 8081 | 10960 | 63469961 |
| Maternal drugs affecting foetus | 32.34 | 14.01 | 15 | 8086 | 5227 | 63475694 |
| Hyperkalaemia | 32.02 | 14.01 | 37 | 8064 | 54166 | 63426755 |
| Hypotension | 30.53 | 14.01 | 90 | 8011 | 272514 | 63208407 |
| Nephrogenic systemic fibrosis | 27.99 | 14.01 | 13 | 8088 | 4543 | 63476378 |
| Blood pressure increased | 27.97 | 14.01 | 63 | 8038 | 161999 | 63318922 |
| Drug intolerance | 26.31 | 14.01 | 4 | 8097 | 308657 | 63172264 |
| Phaeochromocytoma | 25.69 | 14.01 | 7 | 8094 | 512 | 63480409 |
| Cerebral haemorrhage | 23.43 | 14.01 | 24 | 8077 | 30705 | 63450216 |
| Gestational diabetes | 23.06 | 14.01 | 14 | 8087 | 8382 | 63472539 |
| Kidney transplant rejection | 22.61 | 14.01 | 11 | 8090 | 4260 | 63476661 |
| Pulmonary oedema | 22.16 | 14.01 | 31 | 8070 | 54842 | 63426079 |
| Hypertension | 21.27 | 14.01 | 81 | 8020 | 279222 | 63201699 |
| Cerebrovascular accident | 20.91 | 14.01 | 44 | 8057 | 107980 | 63372941 |
| Post transplant lymphoproliferative disorder | 20.90 | 14.01 | 11 | 8090 | 5020 | 63475901 |
| Exomphalos | 20.69 | 14.01 | 6 | 8095 | 551 | 63480370 |
| Proteinuria | 20.41 | 14.01 | 18 | 8083 | 19127 | 63461794 |
| Ultrasound uterus abnormal | 20.21 | 14.01 | 4 | 8097 | 70 | 63480851 |
| Dilatation intrahepatic duct acquired | 19.46 | 14.01 | 6 | 8095 | 680 | 63480241 |
| Neuromuscular blockade | 19.43 | 14.01 | 5 | 8096 | 293 | 63480628 |
| Skin induration | 19.19 | 14.01 | 9 | 8092 | 3214 | 63477707 |
| Placental insufficiency | 18.66 | 14.01 | 7 | 8094 | 1434 | 63479487 |
| Cardiac failure congestive | 18.30 | 14.01 | 38 | 8063 | 92395 | 63388526 |
| Intestinal malrotation | 18.23 | 14.01 | 5 | 8096 | 375 | 63480546 |
| Blood pressure inadequately controlled | 18.21 | 14.01 | 10 | 8091 | 4968 | 63475953 |
| Abortion spontaneous | 18.08 | 14.01 | 26 | 8075 | 47169 | 63433752 |
| Mental status changes | 16.93 | 14.01 | 23 | 8078 | 39576 | 63441345 |
| Bradycardia | 16.77 | 14.01 | 32 | 8069 | 73195 | 63407726 |
| Thymus hypoplasia | 16.62 | 14.01 | 3 | 8098 | 31 | 63480890 |
| Foetal cardiac disorder | 16.62 | 14.01 | 3 | 8098 | 31 | 63480890 |
| Off label use | 16.33 | 14.01 | 39 | 8062 | 674423 | 62806498 |
| Rheumatoid arthritis | 16.31 | 14.01 | 6 | 8095 | 253813 | 63227108 |
| Drug withdrawal syndrome neonatal | 16.17 | 14.01 | 7 | 8094 | 2074 | 63478847 |
| Arthropathy | 16.05 | 14.01 | 5 | 8096 | 234787 | 63246134 |
| Skin hypertrophy | 15.77 | 14.01 | 8 | 8093 | 3383 | 63477538 |
| Infusion related reaction | 15.45 | 14.01 | 6 | 8095 | 245515 | 63235406 |
| Phaeochromocytoma crisis | 15.31 | 14.01 | 4 | 8097 | 249 | 63480672 |
| Cardiac arrest | 14.87 | 14.01 | 35 | 8066 | 92510 | 63388411 |
| Red blood cell schistocytes present | 14.87 | 14.01 | 4 | 8097 | 279 | 63480642 |
| Nipple pain | 14.53 | 14.01 | 4 | 8097 | 304 | 63480617 |
| Decerebration | 14.29 | 14.01 | 3 | 8098 | 71 | 63480850 |
| Gingival hypertrophy | 14.24 | 14.01 | 6 | 8095 | 1665 | 63479256 |
| Treatment failure | 14.03 | 14.01 | 4 | 8097 | 199039 | 63281882 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Premature baby | 151.97 | 17.58 | 67 | 4691 | 19566 | 34932607 |
| Low birth weight baby | 98.67 | 17.58 | 38 | 4720 | 7867 | 34944306 |
| Foetal exposure during pregnancy | 85.10 | 17.58 | 57 | 4701 | 38044 | 34914129 |
| Anhedonia | 68.84 | 17.58 | 29 | 4729 | 7556 | 34944617 |
| Foetal disorder | 68.46 | 17.58 | 17 | 4741 | 809 | 34951364 |
| Neutropenia neonatal | 60.75 | 17.58 | 15 | 4743 | 697 | 34951476 |
| Foetal growth restriction | 55.70 | 17.58 | 21 | 4737 | 4096 | 34948077 |
| Injury | 53.62 | 17.58 | 34 | 4724 | 20653 | 34931520 |
| Fear | 48.09 | 17.58 | 25 | 4733 | 10451 | 34941722 |
| Congenital oesophageal anomaly | 42.95 | 17.58 | 8 | 4750 | 93 | 34952080 |
| Emotional distress | 42.21 | 17.58 | 26 | 4732 | 15000 | 34937173 |
| Renal injury | 35.65 | 17.58 | 21 | 4737 | 11174 | 34940999 |
| Nephrogenic systemic fibrosis | 35.29 | 17.58 | 15 | 4743 | 3990 | 34948183 |
| Maternal exposure during pregnancy | 32.33 | 17.58 | 15 | 4743 | 4903 | 34947270 |
| Patent ductus arteriosus | 31.01 | 17.58 | 13 | 4745 | 3341 | 34948832 |
| Polyhydramnios | 30.47 | 17.58 | 7 | 4751 | 238 | 34951935 |
| Exposure during pregnancy | 26.47 | 17.58 | 16 | 4742 | 8918 | 34943255 |
| Anxiety | 26.43 | 17.58 | 48 | 4710 | 99380 | 34852793 |
| Neonatal respiratory distress | 24.02 | 17.58 | 7 | 4751 | 613 | 34951560 |
| Cardiac arrest | 23.77 | 17.58 | 45 | 4713 | 96114 | 34856059 |
| Newborn persistent pulmonary hypertension | 23.36 | 17.58 | 5 | 4753 | 122 | 34952051 |
| Mental status changes | 22.79 | 17.58 | 27 | 4731 | 38056 | 34914117 |
| Unevaluable event | 22.71 | 17.58 | 25 | 4733 | 32565 | 34919608 |
| Hypertension | 22.34 | 17.58 | 54 | 4704 | 136389 | 34815784 |
| Neonatal cholestasis | 21.59 | 17.58 | 4 | 4754 | 45 | 34952128 |
| Hypotension | 20.98 | 17.58 | 72 | 4686 | 221577 | 34730596 |
| Skin fibrosis | 20.38 | 17.58 | 7 | 4751 | 1045 | 34951128 |
| Pyelocaliectasis | 19.89 | 17.58 | 7 | 4751 | 1123 | 34951050 |
| Ventricular septal defect | 19.66 | 17.58 | 10 | 4748 | 3991 | 34948182 |
| Renal failure | 19.61 | 17.58 | 50 | 4708 | 130507 | 34821666 |
| Skin induration | 18.76 | 17.58 | 8 | 4750 | 2143 | 34950030 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 185.99 | 14.55 | 129 | 9669 | 101003 | 79633587 |
| Pre-eclampsia | 157.91 | 14.55 | 51 | 9747 | 6990 | 79727600 |
| Caesarean section | 122.19 | 14.55 | 49 | 9749 | 12486 | 79722104 |
| Maternal exposure during pregnancy | 71.58 | 14.55 | 86 | 9712 | 136452 | 79598138 |
| Premature delivery | 57.82 | 14.55 | 36 | 9762 | 23431 | 79711159 |
| Premature labour | 55.77 | 14.55 | 25 | 9773 | 8365 | 79726225 |
| Anhedonia | 55.77 | 14.55 | 30 | 9768 | 14868 | 79719722 |
| Nephrogenic systemic fibrosis | 43.01 | 14.55 | 19 | 9779 | 6141 | 79728449 |
| Hypotension | 42.89 | 14.55 | 135 | 9663 | 440182 | 79294408 |
| Fear | 42.57 | 14.55 | 29 | 9769 | 21957 | 79712633 |
| Foetal growth restriction | 38.11 | 14.55 | 13 | 9785 | 2106 | 79732484 |
| Renal injury | 36.80 | 14.55 | 24 | 9774 | 16903 | 79717687 |
| Kidney transplant rejection | 36.59 | 14.55 | 20 | 9778 | 10226 | 79724364 |
| Hypertension | 34.52 | 14.55 | 104 | 9694 | 330888 | 79403702 |
| Cardiac arrest | 33.87 | 14.55 | 69 | 9729 | 172027 | 79562563 |
| Skin induration | 31.73 | 14.55 | 14 | 9784 | 4511 | 79730079 |
| HELLP syndrome | 31.69 | 14.55 | 9 | 9789 | 797 | 79733793 |
| Mental status changes | 31.54 | 14.55 | 40 | 9758 | 66919 | 79667671 |
| Pregnancy | 31.00 | 14.55 | 26 | 9772 | 26825 | 79707765 |
| Renal failure | 29.86 | 14.55 | 72 | 9726 | 200896 | 79533694 |
| Blood pressure increased | 29.58 | 14.55 | 74 | 9724 | 211286 | 79523304 |
| Foetal death | 29.55 | 14.55 | 16 | 9782 | 8028 | 79726562 |
| Emotional distress | 29.24 | 14.55 | 30 | 9768 | 39939 | 79694651 |
| Phaeochromocytoma | 28.73 | 14.55 | 8 | 9790 | 659 | 79733931 |
| Injury | 28.43 | 14.55 | 41 | 9757 | 77455 | 79657135 |
| Cerebral haemorrhage | 28.03 | 14.55 | 35 | 9763 | 57638 | 79676952 |
| Skin hypertrophy | 27.48 | 14.55 | 13 | 9785 | 4915 | 79729675 |
| Cerebrovascular accident | 26.77 | 14.55 | 59 | 9739 | 155233 | 79579357 |
| Myocardial infarction | 26.32 | 14.55 | 65 | 9733 | 184064 | 79550526 |
| Bradycardia | 25.07 | 14.55 | 53 | 9745 | 135504 | 79599086 |
| Anxiety | 24.87 | 14.55 | 77 | 9721 | 248435 | 79486155 |
| Premature baby | 24.28 | 14.55 | 11 | 9787 | 3769 | 79730821 |
| Unevaluable event | 22.75 | 14.55 | 31 | 9767 | 55554 | 79679036 |
| Cardiac failure congestive | 20.05 | 14.55 | 50 | 9748 | 142352 | 79592238 |
| Off label use | 20 | 14.55 | 52 | 9746 | 907163 | 78827427 |
| Dilatation intrahepatic duct acquired | 19.25 | 14.55 | 6 | 9792 | 732 | 79733858 |
| Blood pressure inadequately controlled | 19.18 | 14.55 | 11 | 9787 | 6166 | 79728424 |
| Skin fibrosis | 18.54 | 14.55 | 7 | 9791 | 1517 | 79733073 |
| Drug intolerance | 18.14 | 14.55 | 5 | 9793 | 264114 | 79470476 |
| Abortion spontaneous | 17.79 | 14.55 | 20 | 9778 | 29487 | 79705103 |
| Hypertensive encephalopathy | 17.56 | 14.55 | 6 | 9792 | 976 | 79733614 |
| Placental insufficiency | 16.77 | 14.55 | 6 | 9792 | 1117 | 79733473 |
| Neuromuscular blockade | 16.33 | 14.55 | 5 | 9793 | 575 | 79734015 |
| Red blood cell schistocytes present | 16.25 | 14.55 | 5 | 9793 | 584 | 79734006 |
| Proteinuria | 16.23 | 14.55 | 20 | 9778 | 32482 | 79702108 |
| Completed suicide | 15.87 | 14.55 | 66 | 9732 | 245701 | 79488889 |
| Unresponsive to stimuli | 15.54 | 14.55 | 26 | 9772 | 55762 | 79678828 |
| Coronary artery disease | 14.99 | 14.55 | 28 | 9770 | 65446 | 79669144 |
| Skin tightness | 14.95 | 14.55 | 9 | 9789 | 5513 | 79729077 |
| Stillbirth | 14.90 | 14.55 | 8 | 9790 | 3947 | 79730643 |
| Malignant hypertension | 14.63 | 14.55 | 6 | 9792 | 1616 | 79732974 |
| Pulmonary oedema | 14.60 | 14.55 | 33 | 9765 | 88221 | 79646369 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C07AG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Alpha and beta blocking agents |
| ATC | C07BG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Alpha and beta blocking agents and thiazides |
| ATC | C07CG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND OTHER DIURETICS Alpha and beta blocking agents and other diuretics |
| FDA MoA | N0000000161 | Adrenergic beta-Antagonists |
| FDA EPC | N0000175556 | beta-Adrenergic Blocker |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D058668 | Adrenergic alpha-1 Receptor Antagonists |
| MeSH PA | D000317 | Adrenergic alpha-Antagonists |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D000319 | Adrenergic beta-Antagonists |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D013566 | Sympathomimetics |
| CHEBI has role | CHEBI:35530 | beta-adrenergic blockers |
| CHEBI has role | CHEBI:35674 | antihypertensive drugs |
| CHEBI has role | CHEBI:37890 | alpha-adrenergic receptor blockaders |
| CHEBI has role | CHEBI:66991 | sympatholytic drug |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Angina pectoris | off-label use | 194828000 | |
| Pheochromocytoma Adjunct Therapy | off-label use | ||
| Anuria | contraindication | 2472002 | DOID:2983 |
| Bronchospasm | contraindication | 4386001 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Secondary angle-closure glaucoma | contraindication | 21571006 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Hypovolemia | contraindication | 28560003 | |
| Dehydration | contraindication | 34095006 | |
| Depressive disorder | contraindication | 35489007 | |
| Hyperuricemia | contraindication | 35885006 | DOID:1920 |
| Hypokalemia | contraindication | 43339004 | |
| Low blood pressure | contraindication | 45007003 | |
| Sinus bradycardia | contraindication | 49710005 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Sympathectomy | contraindication | 57071006 | |
| Hepatic failure | contraindication | 59927004 | |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
| Hypochloremic alkalosis | contraindication | 70134007 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Pulmonary emphysema | contraindication | 87433001 | |
| Cardiogenic shock | contraindication | 89138009 | |
| Hyponatremia | contraindication | 89627008 | |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Hypomagnesemia | contraindication | 190855004 | |
| Partial atrioventricular block | contraindication | 195039008 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Neonatal hyperbilirubinemia | contraindication | 281610001 | |
| Intraoperative floppy iris syndrome | contraindication | 418801006 | |
| Azotemia | contraindication | 445009001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.81 | acidic |
| pKa2 | 12.65 | acidic |
| pKa3 | 8.23 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.23 | DRUG MATRIX | CHEMBL | |||
| Beta-2 adrenergic receptor | GPCR | ANTAGONIST | Ki | 7.96 | DRUG MATRIX | CHEMBL | |||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.12 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.48 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.65 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.71 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.89 | DRUG MATRIX | |||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 6.10 | DRUG MATRIX | |||||
| Alpha-1D adrenergic receptor | GPCR | ANTAGONIST | Ki | 7.64 | DRUG MATRIX | ||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.49 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 7.24 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.41 | CHEMBL | |||||
| CAAX prenyl protease 1 | Enzyme | AC50 | 5.11 | CHEMBL | |||||
| CAAX prenyl protease 2 | Enzyme | AC50 | 4.82 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019797 | VUID |
| N0000147886 | NUI |
| D00600 | KEGG_DRUG |
| 32780-64-6 | SECONDARY_CAS_RN |
| 4018799 | VANDF |
| 4019797 | VANDF |
| C0022860 | UMLSCUI |
| CHEBI:6343 | CHEBI |
| CHEMBL429 | ChEMBL_ID |
| DB00598 | DRUGBANK_ID |
| CHEMBL1200323 | ChEMBL_ID |
| D007741 | MESH_DESCRIPTOR_UI |
| 3869 | PUBCHEM_CID |
| 7207 | IUPHAR_LIGAND_ID |
| 3941 | INN_ID |
| R5H8897N95 | UNII |
| 202693 | RXNORM |
| 11828 | MMSL |
| 201477 | MMSL |
| 4950 | MMSL |
| d00016 | MMSL |
| 001839 | NDDF |
| 004368 | NDDF |
| 372750000 | SNOMEDCT_US |
| 46547007 | SNOMEDCT_US |
| 50627005 | SNOMEDCT_US |
| CHEMBL1204165 | ChEMBL_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9320 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 24 sections |
| Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9363 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9363 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9364 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9364 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9365 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9365 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol HCl in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9366 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol HCl in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9366 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9622 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 23 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9623 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 23 sections |
| Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0010 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
| Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0117 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
| Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0118 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 23 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0125 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2267 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2267 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2339 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
| Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0605 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
| Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0606 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
| Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0607 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 22 sections |
| Labetalol HCL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8130 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
| Labetalol HCL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8131 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6252 | INJECTION | 5 mg | INTRAVENOUS | NDA | 26 sections |
| Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5928 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
| Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5929 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
| Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5930 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 22 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7109 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 19 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7110 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 19 sections |
| Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7111 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 19 sections |